Dermata Therapeutics, Inc. (DRMA) Cash Flow Statement

The persistent divergence between net income and operating cash flow suggests that the company's reported losses do not fully capture the cash-intensive nature of its clinical development. Investors should monitor this relationship, as the inability to generate positive operating cash flow necessitates a reliance on external financing to cover ongoing R&D obligations.

The lack of positive free cash flow is an expected characteristic of a clinical-stage biotechnology firm, yet the consistency of these outflows highlights the absence of any self-sustaining operational model. This trajectory implies that the company will continue to experience significant cash erosion until a commercial product or licensing milestone is achieved.

The volatility in working capital movements indicates that management is likely managing cash outflows by timing payments to CROs and other service providers. This practice may provide temporary liquidity relief but does not address the underlying structural deficit inherent in the company's current business model.

The absence of meaningful capital deployment activities suggests that all available resources are being funneled into the Phase 3 clinical program. Investors should interpret this as a clear signal that the company lacks the financial flexibility to pursue anything other than its core R&D objectives.